Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies
- 15 June 2020
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 27 (21) , 3412-3447
Abstract
Glycosaminoglycans (GAGs) are very complex, natural anionic polysaccharides. They are polymers of repeating disaccharide units of uronic acid and hexosamine residues. Owing to their template-free, spatiotemporally-controlled, and enzyme-mediated biosyntheses, GAGs possess enormous polydispersity, heterogeneity, and structural diversity which often translate into multiple biological roles. It is well documented that GAGs contribute to physiological and pathological processes by binding to proteins including serine proteases, serpins, chemokines, growth factors, and microbial proteins. Despite advances in the GAG field, the GAG-protein interface remains largely unexploited by drug discovery programs. Thus, Non-Saccharide Glycosaminoglycan Mimetics (NSGMs) have been rationally developed as a novel class of sulfated molecules that modulate GAG-protein interface to promote various biological outcomes of substantial benefit to human health. In this review, we describe the chemical, biochemical, and pharmacological aspects of recently reported NSGMs and highlight their therapeutic potentials as structurally and mechanistically novel anti-coagulants, anti-cancer agents, anti-emphysema agents, and anti-viral agents. We also describe the challenges that complicate their advancement and describe ongoing efforts to overcome these challenges with the aim of advancing the novel platform of NSGMs to clinical use.Keywords
Funding Information
- National Institute of General Medical Sciences (5 P20 GM103424-15, 3 P20 GM103424- 15S1)
- National Heart, Lung, and Blood Institute (K12 HL141954)
This publication has 234 references indexed in Scilit:
- Identification of the site of binding of sulfated, low molecular weight lignins on thrombinBiochemical and Biophysical Research Communications, 2011
- Rational Design of Potent, Small, Synthetic Allosteric Inhibitors of ThrombinJournal of Medicinal Chemistry, 2011
- Molecular mechanisms of antithrombin–heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitorsBiochimie, 2010
- Chemical sulfation of small molecules—advances and challengesTetrahedron, 2010
- First steps in the direction of synthetic, allosteric, direct inhibitors of thrombin and factor XaBioorganic & Medicinal Chemistry Letters, 2009
- On designing non-saccharide, allosteric activators of antithrombinEuropean Journal of Medicinal Chemistry, 2009
- Capillary electrophoretic study of small, highly sulfated, non‐sugar molecules interacting with antithrombinElectrophoresis, 2009
- Serine proteasesIUBMB Life, 2009
- Finding a Needle in a Haystack: Development of a Combinatorial Virtual Screening Approach for Identifying High Specificity Heparin/Heparan Sulfate Sequence(s)Journal of Medicinal Chemistry, 2006
- Evaluation of the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancerDrug Development Research, 2006